ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.

History

Year	Detail
1999	Founded in 1999, Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.
2001	The company launched an oligo synthesis service.
2002	The company launched LineSilence Kits as the first DNA-based RNAi system and marketed it through Promega.
2003	The company established custom services to carry out CRO projects.
2004	The company initiated the first-ever RNAi workshop series in top universities around China through subsidiary company Allele China.
2006	The company launched its first fluorescent protein product.
2008	The company acquired Orbigen, Inc. and expanded its product line to include about 1,000 antibodies and a baculovirus protein expression system.
2008	In collaboration with AvantGen, the company completed a cancer diagnostics antibody development contract for the National Cancer Institute, NIH.
2009	The company launched Chromotek GFP-Trap and other camelid antibody products.
2009	The company issued a third patent on siRNA and shRNA in the U.S.
2010	The company received funding from NCI/NIH for shRNA screening in cancer-related DNA damage repair pathways.
2011	Allele Biotechnology filed patents: one using enzyme-based ratio enhancement to detect genetic diseases using maternal blood DNA and the second using fluorescent proteins for skin protection.
2014	The company received NIH SBIR grants to develop an all-RNA platform for CRISPR genome modification (NIGMS) and create nanoantibodies (nAb) against mRNA modification groups (NIDA).
2015	The company formed a formal drug development venture with high-content screening company Vala Sciences and launched a joint drug development service that included kinetic imaging and histology analysis.
2019	The company announced a joint research and development agreement with South Korea’s SCM Lifescience Co., Ltd. to develop diabetes therapies using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs).
2019	Allele partnered with Addgene to increase academic access to the monomeric fluorescent protein.
2019	The company entered a research agreement with Alpine BioTherapeutics Corp. to develop iPSC-derived cell therapy for treating retinal diseases.
2024	Cellular Logistics Inc. and Allele entered a collaboration to develop regenerative medicine products to treat ischemic heart disease.
2024	California Institute for Regenerative Medicine (CIRM) partnered with Allele to accelerate regenerative medicine product development in California.